Constantino Kantaridis

A first‐in‐human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF‐06741086, an anti‐tissue factor pathway inhibitor mAb, in healthy volunteers

Matthew Cardinal, Constantino Kantaridis, Tong Zhu et al. · Journal of Thrombosis and Haemostasis · 2018 · 75 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +6

Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects

Huiping Xu, Melissa O’Gorman, Tanya Boutros et al. · The Journal of Clinical Pharmacology · 2014 · 45 citations

Pharmacy, Pharmacokinetics, Pharmacology +15

Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1–infected patients

Frank Wagner, Robert W. Thompson, Constantino Kantaridis et al. · Hepatology · 2011 · 45 citations

Medicine, Pharmacology, Pharmacotherapy +17

Pharmacokinetic and Pharmacodynamic Effects of a γ‐Secretase Modulator, <scp>PF</scp>‐06648671, on <scp>CSF</scp> Amyloid‐β Peptides in Randomized Phase I Studies

Jae Eun Ahn, Charles Carrieri, Fernando Dela Cruz et al. · Clinical Pharmacology & Therapeutics · 2019 · 35 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Phase 1 dose‐escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXaI16L)

Dana Parsons‐Rich, Fei Hua, Guozhong Li et al. · Journal of Thrombosis and Haemostasis · 2017 · 26 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +9